NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

全球体外诊断用医药品 (IVD) 的联盟契约趋势:2010-2016年

Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品编码 355308
出版日期 内容资讯 英文 350+ Pages
订单完成后即时交付
价格
全球体外诊断用医药品 (IVD) 的联盟契约趋势:2010-2016年 Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021
出版日期: 2021年05月01日内容资讯: 英文 350+ Pages
简介

本报告提供体外诊断用医药品 (IVD) 相关的各种联盟契约趋势的相关调查,近几年所签订的各种契约趋势,大规模契约及大型经营者的契约概要,契约区分、开发阶段、治疗领域、各技术类型的一览等汇整资料。

第1章 简介

第2章 体外诊断用医药品 (IVD) 相关合约趋势

  • 简介
  • 过去数年的联盟趋势
  • 联盟契约最活跃的经营者
  • 联盟契约:各契约种类
  • 联盟契约:各治疗领域
  • 联盟契约的条件
    • 交易总额
    • 契约退职金
    • 里程碑付款
    • 权利金比率

第3章 主要契约

  • 简介
  • 主要契约:各契约金额

第4章 联盟契约最活跃的经营者

  • 简介
  • 联盟契约最活跃的经营者
  • 联盟契约最活跃的经营者简介

第5章 联盟契约目录

  • 简介
  • 联盟契约目录

第6章 体外诊断用医药品 (IVD) 相关合约:各技术区分

第7章 联盟契约资源中心

  • 线上基于的联盟
  • 联盟活动
  • 联盟契约相关资料

附录1:联盟契约 - 各企业 (A-Z)

附录2:联盟契约 - 各开发阶段

  • 药物研发
  • 前临床
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 申请阶段
  • 已上市
  • 调剂阶段

附录3:联盟契约 - 各类型

  • 资产购买
  • 转让
  • 生物医药品对外授权
  • 共同开发
  • 共同R&D
  • 共同贩卖
  • 共同促销
  • CRADA
  • 交叉授权
  • 开发
  • 流通销售
  • 股票购买
  • 评估
  • 津贴
  • 合资企业
  • 授权
  • 诉讼
  • 制造
  • 行销
  • 物质移动
  • 选择
  • 推销
  • 研究
  • 协定
  • 衍生公司
  • 辅助许可证
  • 供给
  • 技术转移
  • 契约解除
  • 保证

附录4:联盟契约 - 各治疗领域

附录5 -联盟区分定义

关于Wildwood Ventures

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: CP2120

Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the in vitro diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies

The Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021 report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest In Vitro Diagnostics agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review In Vitro Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering In Vitro Diagnostics partnering deals.

The report presents financial deal term values for In Vitro Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the In Vitro Diagnostics partnering field; both the leading deal values and most active In Vitro Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 600 online deal records of actual In Vitro Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of In Vitro Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in In Vitro Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading In Vitro Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in In Vitro Diagnostics dealmaking with a brief summary followed by a comprehensive listing of In Vitro Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of In Vitro Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of In Vitro Diagnostics partnering deals signed and announced since Jan 2014. The chapter is organized by specific In Vitro Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by In Vitro Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in In Vitro Diagnostics partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of In Vitro Diagnostics technologies and products.

Key benefits

Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021 provides the reader with the following key benefits:

  • In-depth understanding of In Vitro Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual In Vitro Diagnostics contracts entered into by leading biopharma companies
  • Identify most active In Vitro Diagnostics dealmakers since 2014
  • Insight into terms included in a In Vitro Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021 is intended to provide the reader with an in-depth understanding and access to In Vitro Diagnostics trends and structure of deals entered into by leading companies worldwide.

In Vitro Diagnostics Partnering Terms and Agreements includes:

  • Trends in In Vitro Diagnostics dealmaking in the biopharma industry since 2014
  • Analysis of In Vitro Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to In Vitro Diagnostics contract documents
  • Leading In Vitro Diagnostics deals by value since 2014
  • Most active In Vitro Diagnostics dealmakers since 2014

In Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021 report provides comprehensive access to available deals and contract documents for over 600 In Vitro Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021 report provides the reader with the following key benefits:

  • In-depth understanding of In Vitro Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual In Vitro Diagnostics contracts entered into by leading biopharma companies
  • Identify most active In Vitro Diagnostics dealmakers since 2014
  • Insight into terms included in a In Vitro Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in In Vitro Diagnostics dealmaking

  • 2.1. Introduction
  • 2.2. In Vitro Diagnostics partnering over the years
  • 2.3. Most active In Vitro Diagnostics dealmakers
  • 2.4. In Vitro Diagnostics partnering by deal type
  • 2.5. In Vitro Diagnostics partnering by therapy area
  • 2.6. Deal terms for In Vitro Diagnostics partnering
    • 2.6.1 In Vitro Diagnostics partnering headline values
    • 2.6.2 In Vitro Diagnostics deal upfront payments
    • 2.6.3 In Vitro Diagnostics deal milestone payments
    • 2.6.4 In Vitro Diagnostics royalty rates

Chapter 3 - Leading In Vitro Diagnostics deals

  • 3.1. Introduction
  • 3.2. Top In Vitro Diagnostics deals by value

Chapter 4 - Most active In Vitro Diagnostics dealmakers

  • 4.1. Introduction
  • 4.2. Most active In Vitro Diagnostics dealmakers
  • 4.3. Most active In Vitro Diagnostics partnering company profiles

Chapter 5 - In Vitro Diagnostics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. In Vitro Diagnostics contracts dealmaking directory

Chapter 6 - In Vitro Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - In Vitro Diagnostics deals by company A-Z
  • Appendix 2 - In Vitro Diagnostics deals by stage of development
  • Apppendix 3 - In Vitro Diagnostics deals by deal type
  • Appendix 4 - In Vitro Diagnostics deals by therapy area
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: In Vitro Diagnostics partnering since 2014
  • Figure 2: Active In Vitro Diagnostics dealmaking activity since 2014
  • Figure 3: In Vitro Diagnostics partnering by deal type since 2014
  • Figure 4: In Vitro Diagnostics partnering by disease type since 2014
  • Figure 5: In Vitro Diagnostics deals with a headline value
  • Figure 6: In Vitro Diagnostics deals with an upfront value
  • Figure 7: In Vitro Diagnostics deals with a milestone value
  • Figure 8: In Vitro Diagnostics deals with a royalty rate value
  • Figure 9: Top In Vitro Diagnostics deals by value since 2014
  • Figure 10: Most active In Vitro Diagnostics dealmakers since 2014
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events